PULM - רווח נקי למניה (EPS TTM) Pulmatrix Inc

Pulmatrix, Inc. (PULM) maintains transparent scientific management of its trials, yet a funding shortage is forcing the company to deplete its accumulated reserves for R&D. The TTM net income per share serves as an indicator of this trend, where the current parameter equals -1.09. Business development relies on iSPERSE technology, which creates effective inhalation therapy methods for treating lung diseases.

TTM net income per share measures the owner's portion of the final annual financial result, excluding the impact of the total number of shares. By analyzing the trend, an investor separates fundamental growth from market volatility. The price action of the TTM annual earnings per share reveals the gap between accounting profit and actual cash flow. For Pulmatrix, Inc. (PULM), this metric reflects the commercialization efficiency of the iSPERSE platform. The success of innovations in inhalation drug delivery will directly determine the future growth of this indicator.